A Tale of Two Periods: The Evolution of Determinants and CVD Mortality Risk in Metastatic NSCLC
Survival of patients with metastatic NSCLC has improved significantly since the introduction of immunotherapy. However, survival differences between some subpopulations continue to intensify, while CVD mortality risk also remains a key concern.
Authors
- Junyan Xia (ORCID: https://orcid.org/0000-0001-7899-2175)
- Yanting Pang
- Qian Lin (ORCID: https://orcid.org/0000-0001-8980-2269)
- Yiqiu Yang
- Jun Teng (ORCID: https://orcid.org/0009-0004-3157-7678)
Institutions
- Beijing University of Chinese Medicine (CN)
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (CN)
Publication Details
- Journal
- Reviews in Cardiovascular Medicine
- Published
- 2025-09-28
- DOI
- https://doi.org/10.31083/rcm39296
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00